Alterity Therapeutics updates registered office

Alterity Therapeutics Limited, a development stage enterprise listed on ASX and Nasdaq, filed a Form 6-K to report an administrative change.

Rhea-AI Filing Summary

Alterity Therapeutics Limited, a development stage enterprise listed on ASX and Nasdaq, filed a Form 6-K to report an administrative change. The company has changed its registered office address to Level 15, 500 Collins Street, Melbourne, VIC 3000, effective 3 June 2026. The report notes that this Form 6-K is incorporated by reference into several existing Form S-8 and Form F-3 registration statements.

Key Terms

Form 6-K, foreign private issuer, Form S-8, Form F-3, +1 more

5 terms

Form 6-K regulatory

"SECURITIES AND EXCHANGE COMMISSION FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

foreign private issuer regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Form S-8 regulatory

"incorporated by reference into our Registration Statement on Form S-8"

A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.

Form F-3 regulatory

"and our Registration Statements on Form F-3 (Files No. 333-274816"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

ASX Listing Rule 3.14 regulatory

"for the purposes of ASX Listing Rule 3.14, the Company’s registered office address has changed"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Alterity Therapeutics (ATHE) disclose in this Form 6-K?

Alterity Therapeutics disclosed an administrative change to its registered office address. The company reported that, effective 3 June 2026, its registered office is now Level 15, 500 Collins Street, Melbourne, VIC 3000, under ASX Listing Rule 3.14 requirements.

What is the new registered office address for Alterity Therapeutics (ATHE)?

Alterity Therapeutics’ new registered office is Level 15, 500 Collins Street, Melbourne, VIC 3000. This change is effective from 3 June 2026 and was announced to comply with ASX Listing Rule 3.14 regarding changes to a company’s registered office details.

When did Alterity Therapeutics’ registered office change become effective?

The change of registered office for Alterity Therapeutics became effective on 3 June 2026. The company advised this timing in its announcement, made under ASX Listing Rule 3.14, and documented the change in a Form 6-K filed with the U.S. Securities and Exchange Commission.

Why did Alterity Therapeutics issue a Form 6-K for the address change?

Alterity Therapeutics issued a Form 6-K because, as a foreign private issuer, it reports certain material or regulatory updates to the SEC. The company used this form to formally notify investors of its new registered office address effective 3 June 2026.

Which registration statements incorporate this Alterity Therapeutics Form 6-K by reference?

This Form 6-K is incorporated by reference into Alterity Therapeutics’ Form S-8 registration statements (File Nos. 333-251073, 333-248980, 333-228671) and Form F-3 registration statements (File Nos. 333-274816, 333-251647, 333-231417, 333-250076), aligning the address information across filings.

Who authorized the announcement of Alterity Therapeutics’ address change?

The announcement of Alterity Therapeutics’ address change was authorized by the company’s Board of Directors. The Form 6-K is signed on behalf of the registrant by Chairman Julian Babarczy, confirming board-level approval of this administrative update.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 06:03 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Alterity Therapeutics Limited

(Name of Registrant)

Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

The following exhibits are submitted:

99.1 Change of Registered Office Address

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Alterity Therapeutics Limited
	By:	/s/ Julian Babarczy
		Julian Babarczy
		Chairman

Date: June 3, 2026

2

Exhibit 99.1

Change of Registered Office Address

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 3 June 2026:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) wishes to advise that for the purposes of ASX Listing Rule 3.14, the Company’s registered office address has changed to the below, effective 3 June 2026.

Address:

Level 15, 500 Collins Street

Melbourne

VIC 3000.

This announcement was authorised by the Board of Directors of Alterity Therapeutics Limited.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 3.2 KB